Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received a consensus rating of “Buy” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $34.7778.

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 22nd. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Canaccord Genuity Group lifted their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Finally, Wedbush upped their price objective on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th.

Stoke Therapeutics Trading Down 0.8%

STOK opened at $31.92 on Monday. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69. The firm has a market capitalization of $1.82 billion, a PE ratio of 47.64 and a beta of 1.14. The firm’s 50-day moving average price is $30.09 and its 200 day moving average price is $22.33.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. As a group, analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel Jonathan Allan sold 3,978 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.28, for a total value of $128,409.84. Following the transaction, the general counsel directly owned 11,831 shares in the company, valued at approximately $381,904.68. This represents a 25.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 3,662 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $31.34, for a total value of $114,767.08. Following the completion of the transaction, the insider owned 19,798 shares of the company’s stock, valued at $620,469.32. The trade was a 15.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 182,166 shares of company stock valued at $5,136,957 in the last 90 days. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock worth $18,515,000 after purchasing an additional 53,004 shares during the period. Invesco Ltd. lifted its position in Stoke Therapeutics by 117.0% in the first quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock valued at $174,000 after buying an additional 14,118 shares during the last quarter. Nuveen LLC purchased a new position in Stoke Therapeutics during the first quarter worth about $719,000. Russell Investments Group Ltd. purchased a new position in Stoke Therapeutics during the first quarter worth about $107,000. Finally, Wellington Management Group LLP increased its position in shares of Stoke Therapeutics by 0.9% during the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock valued at $904,000 after acquiring an additional 1,148 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.